Randomised clinical trial of an intensive intervention into life-styles of patients with hyperfibrinogenaemia in primary prevention of cardiovascular pathology in primary health care;Ensayo clínico aleatorizado de una intervención intensiva sobre los estilos de vida de pacientes con hiperfibrinogenemia en prevención primaria de las enfermedades cardiovasculares en el ámbito de la atencion primaria de salud

Atencion Primaria

Volumn 35, Issue 5, 2005, Pages 260-264

  Rodríguez Cristóbal, Juan José ^a   Benavides Marquez F ^b   Villaverde Grote, C ^c   Pena Sendra E ^c   Flor Serra, F ^d   Trave Mercade P ^e  

^a ABS Florida Sud   (Spain)

^b Prosperitat   (Spain)

^c CSIC   (Spain)

^d ICS SAP Hospitalet Barcelona   (Spain)

^e Laboratorio de Analisis Clinicos   (Spain)

Author keywords

Cardiovascular risk; Fibrinogen; Life style changes

Indexed keywords

CHOLESTEROL; FIBRINOGEN; LIPID;

ADULT; AGED; ARTICLE; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL TRIAL; DIABETES MELLITUS; EXERCISE; FEMALE; FIBRINOGEN BLOOD LEVEL; HEALTH PROMOTION; HUMAN; HYPERTENSION; LIFESTYLE; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; OBESITY; PATIENT COUNSELING; PHYSICAL ACTIVITY; PRIMARY HEALTH CARE; QUALITY OF LIFE; RANDOMIZATION; RISK FACTOR; SMOKING CESSATION; SPAIN;

EID: 17644414909     PISSN: 02126567     EISSN: None     Source Type: Journal    
DOI: 10.1157/13072792     Document Type: Article

References (20)

1. Villar Álvarez F, Maiques Galán A, Brotons Cuixart C, Torcal Laguna J, Lorenzo Piqueres A, Vilaseca Canals J, et al. Prevención de las enfermedades cardiovasculares en atención primaria. Aten Primaria. 2001;28 Supl 2:13-26.
2. Villaverde CA. Fibrinógeno como factor de riesgo cardiovascular. Incidencia de los fibratos. Cardiovascular Risk Factors. 1994;3 Suppl 2:30-45.
3. Downs JR, Clearfield M, Weis S, et al. Prevención primaria de los eventos coronarios agudos con lovastatina en varones y mujeres con concentraciones promedio de colesterol. Resultados del AFCAPS/TexCAPS. JAMA (ed. esp.). 1998;7:8.
4. Fowkes FG. Fibrinogen and cardiovascular disease in clinical practice. Eur Heart J. 1995;16 Suppl A:60-3.
5. Ernst E, Resch KL. Fibrinogen as cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993;118:956-63.
6. Dotevall A, Johansson S, Wilhelmsen L. Associaton between fibrinogen and other risk factor for cardiovascular disease in men and women. Results from the Goteborg MONICA survey 1985. Ann-Epidemiol. 1994;4:369-74.
7. Ernst E, Resch KL. Therapeutic interventions to lower plasma fibrinogen concentration. Eur Heart J. 1995;16 Suppl A:47-53.
8. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease:meta-analyses of prospective studies. JAMA. 1998;279:1477-82.
9. Masiá R, Pena A, Marrugat J, Sala J, Vila J, Pavesi M, et al, and the REGICOR Investigators. High prevalence of cardiovascular risk factors in Gerona, Spain. A province with low myocardial infarction incidence. J Epidemiol Community Health. 1998;52:707-15.
10. Gil B, Avilés J, Maldonado A, Fernández M. Factores de riesgo en ancianos. Estudio de 143 pacientes. An Med Interna (Madrid). 1997;14:495-9.
11. Rodriguez JJ, Villaverde CA, Torelló L, Trocho C, Tibau N, Villaverde AA. Relationship between colesterol and fibrinogen in primary-care areas. Dublin: 15th Wonca World Conference. 1998. p. 178.
12. Rodriguez JJ, Villaverde CA, Trocho C, Ortiz Y, Tibau N, Villaverde A. Significado de la hiperfibrinogenemia e hipercolesterolemia como marcadores de riesgo cardiovascular en relación con la localización geográfica de la población. XVIII Congreso Nacional de Medicina de Familia y comunitaria. Aten Primaria. 1998;22:348.
13. Yano K, Grove J, Chen R, Rodríguez BL, Curb JD, Tracy RP. Plasma fibrinogen as a predictor of total and cause-specific mortality in elderly Japanese-american men. Arterioscl Thromb Vasc Biol. 2001;21:1065-70.
14. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä. Prevention of coronary heart disease in clinical practice. Summary of recommendations the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J Atherosclerosis. 1998;140:199-270.
15. Kannel WB. Influence of fibrinogen on cardiovascular disease. Drugs. 1997;54 Suppl 3:32-40.
16. Rodriguez JJ, Villaverde CA, Tibau N, Flor F, Mateos F, Peña E. Relationship of cardiovascular risk to plasma concentrations of fibrinogen. Finlandia, Tampere 2001, Conference of European Society of General Practice/Family Medicine. Wonca Region Europe, p. 139.
17. Vilaseca J, Casajuana J, Ciurana R, Maiques A, Mundet X. Hipercolesterolemia: protocolo de actuación. Sociedad Española de Medicina Familiar y Comunitaria. Barcelona: Ediciones Doyma, S.L.; 2000. p. 5.
18. Woolf S, Jonas S, Lawrence R. Health promotion and disease prevention in clinical practice. Nueva York: Williams and Wilkins; 1996. p. 177-223.
19. Córdoba García R, Ortega Sánchez-Pinilla R, Cabezas Peña C, Forés Garcia D, Nebot Adell M, Robledo de Dios T. Recomendaciones sobre estilo de vida. Aten Primaria. 2001;28 Supl 2:27-41.
20. Hooper L, Summerbell C, Higgins J, Thompson R, Capps N, Smith GD, et al. Dietary fat intake and prevention of cardiovascular disease: systematic review. BMJ. 2001;322:757-63.